Photodynamic therapy for choroidal hemangioma

Shields, Jerry A.

doi:10.1007/s00417-005-0185-2

Cited by 15 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, although there are occasional reports of choroidal hemangioma that showed apparent enlargement, total retinal detachment and neovascular glaucoma, the natural course is generally one of stability or rarely enlargement and exudation [15]. In case of enlargement and symptomatic alterations, when leakage leads to subretinal exudation, and serous retinal detachment involves the macula, PDT has emerged as the new standard of care.…”

Section: Photodynamic Therapy Of Ocular Tumorsmentioning

confidence: 99%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

et al. 2007

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has become a well-established treatment for vascular forms of age-related macular degeneration (AMD). The implementation of evidence-based medicine principles into the treatment regimen of AMD seems to be immensly important, since AMD continues to be the most frequent cause of blindness among patients older than 65 years in industrialized countries. Numerous randomized prospective studies demonstrated high levels of evidence for the efficacy of various treatment approaches such as laser photocoagulation, PDT, subretinal surgery or novel anti-angiogenic drugs [Arch Ophthalmol 2006;124:597–599]. The high evidence shown by these studies supported the rationale to use PDT also in additional, less frequent, vasoproliferative diseases. Although these ‘case series’ and ‘individual case control studies’ have a low level of evidence, they give us important information for treatment decisions in these rare conditions. The goal of this survey is to review the current literature regarding PDT in vasoproliferative and exudative ocular diseases outside AMD. Many studies modified the treatment parameters of PDT to address the specific pathology of the underlying disease. Table 1 summarizes the diseases and treatment parameters that are described in this part 2, the entire table of this review is included in part 1 (www.karger.com/doi/10.1159/ 000101922).

show abstract

Section: Photodynamic Therapy Of Ocular Tumorsmentioning

confidence: 99%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

et al. 2007

View full text Add to dashboard Cite

show abstract

“…[10] PDT, in contrast, spares the overlying retina and has efficacy in both reducing CCH thickness and causing resolution of associated serous SRF, resulting in stability or improvement of visual acuity (Figure 1). [11][12][13][14][15] Shields et al, in a series of 458 cases, found that the management of CCH in the PDT era has allowed for improved visual acuity outcomes compared with the pre-PDT era, with mean final visual acuity of 20/63 (PDT era) versus 20/400 (pre-PDT era). [16] Ho et al reported that patients presenting before the age of 50 years with pretreatment best-corrected visual acuity (BCVA) ≥ 20/200 and less foveal edema were most likely to benefit from PDT.…”

Section: Circumscribed Choroidal Hemangiomamentioning

confidence: 99%

Photodynamic Therapy in Ocular Oncology

Mazloumi

Dalvin

Abtahi

et al. 2020

JOVR

View full text Add to dashboard Cite

Over the past two decades, we have witnessed the increasing use of photodynamic therapy (PDT) in the field of ocular oncology. Based on a review of the literature and our own experience, we herein review the role of PDT for the management of intraocular tumors. The discussion includes two main topics. First, we discuss the application of PDT for benign tumors, including circumscribed choroidal hemangioma, choroidal osteoma, retinal astrocytoma, retinal capillary hemangioma (retinal hemangioblastoma), and retinal vasoproliferative tumor. Second, we assess the role of PDT for malignant tumors, including choroidal melanoma and choroidal metastasis.

show abstract

“…Periorbital IHs have an adverse impact on the visual axis. Obstruction of the visual axis results in stimulus deprivation amblyopia 41,42 . Pressure on the cornea can lead to astigmatism, which can cause permanent amblyopia.…”

Section: Complicationsmentioning

confidence: 99%

“…Pressure on the cornea can lead to astigmatism, which can cause permanent amblyopia. Other ophthalmic complications associated with periorbital IHs include tear duct obstruction, proptosis, ptosis, strabismus and myopia 41–43 . Infants with these IHs are in need of immediate ophthalmological evaluation.…”

Section: Complicationsmentioning

confidence: 99%

Infantile haemangiomas: a challenge in paediatric dermatology

Schwartz¹,

Sidor

Musumeci

et al. 2010

Acad Dermatol Venereol

View full text Add to dashboard Cite

Infantile haemangiomas, common benign vascular tumours of childhood, are characterized by rapid growth during the first year of life and a slow regression that is usually completed at 7-10 years of age. These tumours are composed of endothelial cells with high mitotic rates and stromal components such as fibroblasts, mast cells and pericytes. Haemangiomas become a challenge when they are part of a syndrome, are located in certain areas of the body or when complications develop. The above-mentioned factors also influence the treatment modality used. However, although there remain many uncertainties regarding management, the beta-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. It produces such a dramatic and rapid response that the appearance of an infantile haemangioma should impart expeditious consideration of the risks and benefits of its use.

show abstract

Photodynamic therapy for choroidal hemangioma

Cited by 15 publications

References 3 publications

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

Photodynamic Therapy in Ocular Oncology

Infantile haemangiomas: a challenge in paediatric dermatology

Contact Info

Product

Resources

About